TCRs In Personalized Oncology With BlueSphere Bio's Keir Loiacono
Business Of Biotech
00:00
Blue Sphere's Strategy to Crack the Solid Tumor Nut
TCX 201 is an alginiac drug, which also brings as you talked about the challenges within the response and things like that. We just completed a, a really comprehensive strategic review where we went out to people all across different sectors. And we really pressure tested this concept of using these minor histocompatibility antigens or MIHAZ in our first trial. Because we haven't changed who we are right? We're not inheriting something that has been invested millions of dollars yet,. But it's not too late to turn around because we're a platform company.
Transcript
Play full episode
